Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib + Fulvestrant in ER+/HER2- Advanced Breast Cancer
NCT02756364Phase 2Completed
- Sponsor
- Calithera Biosciences
- Start
- Jul 2016
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of sapanisertib in estrogen receptor-positive breast cancer (ER+) (3 arms), sponsored by Calithera Biosciences. Primary endpoint: Progression Free Survival at 40 months. Started Jul 2016; status: completed.
02
Drugs
sapanisertib
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT02756364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756364.